| 1 |
Tumlin JA, Madaio MP, Hennigar R. Idiopathic IgA nephropathy: pathogenesis, histopathology, and therapeutic options [J]. Clin J Am Soc Nephrol, 2007, 2(5):1054-1061.
|
| 2 |
史伟. IgA肾病[M]. 北京，人民卫生出版社，2009.
|
| 3 |
Floege J, Feehally J. IgA nephropathy: recent developments [J]. J Am Soc Nephrol, 2000, 11(12):2395-2403.
|
| 4 |
Barratt J, Feehally J. Primary IgA nephropathy: new insights into pathogenesis [J]. Semin Nephrol, 2011, 31(4):349-360.
|
| 5 |
Falk RJ, Jennetle C, Patrick H. Primary glomerular disease. In: Brenner & Rector′s, The Kidney, 8th edition, Phladelphia: Saunders WB. 2004: 1333-1338.
|
| 6 |
Cattran DC, Coppo R, Cook HT, et al. The Oxford classification of IgA nephropathy : rationale, clinicopathological correlations, and classification [J]. Kidney Int, 2009, 76(5):534-545.
|
| 7 |
Salvadori M, Rosso G. Update on immunoglobulin a nephropathy. Part II: Clinical, diagnostic and therapeutical aspects [J]. World J Nephrol, 2016, 5(1):6-19.
|
| 8 |
KDIGO Work Group. KDIGO clinical practice guidelines for glomerulonephritis [J]. Kidney Int Suppl, 2012, 2(1):209-217.
|
| 9 |
Radhakrishnan J, Cattran DC. The KDIGO practice guideline on glomerulonephritis: reading between the (guide) lines-application to the individual patient [J]. Kidney Int, 2012, 82(8):840-856.
|
| 10 |
Tesar V, Troyanov S, Bellur S, et al. Corticosteroids in IgA nephropathy: a retrospective analysis from the VALIGA study [J]. J Am Soc Nephrol, 2015, 26(9):2248-2258.
|
| 11 |
Kobayashi Y, Hiki Y, Kokubo T, et al. Steroid therapy during the early stage of progressive IgA nephropathy. A 10 year follow-up study [J]. Nephron, 1996, 72(2):237-242.
|
| 12 |
Pozzi C, Bolasco P, Fogazzi G, et al. Corticosteroid in IgA nephropathy：a randomzsed controlled trial [J]. Lancet, 1999, 353(9156):883-887.
|
| 13 |
Kuriki M, Asahi K, Asano K, et al. Steroid therapy reduces mesangial matrix accumulation in advanced IgA nephropathy [J]. Nephrol Dial Transplant, 2003, 18(7):1311-1315.
|
| 14 |
Pozzi C, Andrulli S, Vecchio LD, et al. Corticosteroid effectiveness in IgA nephropathy: long-term results of a randomized, controlled trial [J]. J Am Soc Nephrol, 2004, 15(1):157-163.
|
| 15 |
Lv J, Zhang H, Chen Y, et al. Combination therapy of prednisone and ACE inhibitor versus ACE-inhibitor therapy alone in patients with IgA nephropathy: a randomized controlled trial [J]. Am J Kidney Dis, 2009, 53(1):26-32.
|
| 16 |
Sarcina C, Tinelli C, Ferrario F, et al. Changes in proteinuria and side effects of corticosteroids alone or in combination with azathioprine at different stages of IgA nephropathy [J]. Clin J Am Soc Nephrol, 2016, 11(6):973-981.
|
| 17 |
Barratt J, Feehally J. Treatment of IgA nephropathy [J]. Kidney Int, 2006, 69(11):1934-1938.
|
| 18 |
Herlitz LC, Bomback AS, Stokes MB, et al. IgA nephropathy with minimal change disease [J]. Clin J Am Soc Nephrol, 2014, 9(6):1033-1039.
|
| 19 |
Ballardie FW, Roberts IS. Controlled prospective trial of prednisolone and cytotoxics in progressive IgA nephropathy [J]. J Am Soc Nephrol, 2002, 13(1):142-148.
|
| 20 |
Harper L, Ferreira MA, Howie AJ, et al. Treatment of vasculitic IgA nephropathy [J]. J Nephrol, 2000, 13(5):360-366.
|
| 21 |
Tumlin JA, Lohavichan V, Hennigar R. Crescentic, proliferative IgA nephropathy: clinical and histological response to methylprednisolone and intravenous cyclophosphamide [J]. Nephrol Dial Transplant, 2003, 18(7):1321-1329.
|